BioSpace

Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager

Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.

By BioSpace

1 min read
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights